Japan

Amgen wades deeper into Asia with full control of an Astellas Japanese JV
Amgen wades deeper into Asia with full control of an Astellas Japanese JV
Fierce Pharma
Amgen
Astellas
Japan
BeiGene
China
Flag link:
ViiV’s two-drug HIV therapy Dovato gets Japanese approval
ViiV’s two-drug HIV therapy Dovato gets Japanese approval
Pharmaforum
ViiV Healthcare
Dovato
HIV
Japan
Flag link:
Gilead gets ball rolling on JAKs game in Japan
Gilead gets ball rolling on JAKs game in Japan
Endpoints
Gilead Sciences
Japan
filgotinib
Eisai
rheumatoid arthritis
Flag link:
Japan Approves Genetic Testing For Breast Cancer Treatment
Japan Approves Genetic Testing For Breast Cancer Treatment
Forbes
Japan
genetic testing
breast cancer
BRACAnalysis CDx
Myriad Genetics
diagnostics
Flag link:
Japan's Kyowa Kirin reorganizes quality responsibilities
Japan's Kyowa Kirin reorganizes quality responsibilities
Fierce Pharma
Japan
Kyowa Hakko Kirin
Parkinson's Disease
pharmacovigilance
Quality Assurance
Nourianz
Flag link:
Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'
Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'
Endpoints
Roche
Xofluza
Japan
Shionogi
Flu
influenza
Flag link:
Novartis' Generics Unit to Buy Aspen's Japanese Operations
Novartis' Generics Unit to Buy Aspen's Japanese Operations
Yahoo/Zacks.com
Novartis
generics
Sandoz
M&A
Japan
Aspen Pharmacare
Aspen Global
Flag link:
Novo Nordisk buys rights to NASH drug from Japan’s UBE
Novo Nordisk buys rights to NASH drug from Japan’s UBE
Pharmaforum
Novo Nordisk
NASH
Japan
UBE
UD-014
Flag link:
Biogen signs marketing deal for two ophthalmology biosimilars
Biogen signs marketing deal for two ophthalmology biosimilars
Pharmaforum
Biogen
ophthalmology
biosimilars
Europe
Japan
Samsung Bioepis
SB11
SB15
Lucentis
Eylea
Flag link:
Chasing AbbVie, Gilead files for approval of filgotinib in Japan
Chasing AbbVie, Gilead files for approval of filgotinib in Japan
Fierce Biotech
Gilead Sciences
JAK inhibitors
Japan
filgotinib
Galapagos
AbbVie
Flag link:
Still seeking cost cuts, Sanofi plans to slim down in Japan through voluntary retirements
Still seeking cost cuts, Sanofi plans to slim down in Japan through voluntary retirements
Fierce Pharma
Sanofi
Japan
job cuts
Flag link:
Chasing Astellas and Mitsubishi, GSK files for Japanese approval of oral anemia drug
Chasing Astellas and Mitsubishi, GSK files for Japanese approval of oral anemia drug
Fierce Biotech
GSK
Japan
renal anemia
daprodustat
Flag link:
Astellas tests gamification ideas with Japanese universities
Astellas tests gamification ideas with Japanese universities
Pharmaforum
Astellas
Japan
gamification
Flag link:
Look out, Bayer: Roche scores first global nod for targeted cancer drug Rozlytrek
Look out, Bayer: Roche scores first global nod for targeted cancer drug Rozlytrek
Fierce Pharma
Roche
Rozlytrek
Japan
cancer
Bayer Vitrakvi
Flag link:
Daiichi Sankyo comes up way short of promised avian flu vaccine production
Daiichi Sankyo comes up way short of promised avian flu vaccine production
Fierce Pharma
Daiichi Sankyo
vaccines
Japan
avian flu
drug shortages
Flag link:
Roche's Chugai to set up new $1B+ lab in Yokohama, consolidating R&D
Roche's Chugai to set up new $1B+ lab in Yokohama, consolidating R&D
Endpoints
Chugai
Roche
Japan
R&D
Flag link:
Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K
Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K
Endpoints
Novartis
Kymriah
Japan
CAR-T
Flag link:
Here's Why Athersys Is Soaring Today
Here's Why Athersys Is Soaring Today
Motley Fool
Athersys
Japan
clinical trials
stem cells
MultiStem
ARDS
Flag link:
Trial sets up 2020 filing for Poxel’s novel diabetes drug
Trial sets up 2020 filing for Poxel’s novel diabetes drug
Pharmaforum
Poxel
Japan
diabetes
type 2 diabetes
clinical trials
imeglimin
Flag link:
AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales
AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales
Endpoints
AbbVie
Japan
psoriasis
risankizumab
Skyrizi
Flag link:

Pages